First Week of March 20th Options Trading For Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies (ADPT) trades at $17.86; a $17.50 put is bid $0.10 (implying a $17.40 net cost basis if sold, ~2% OTM) with a 58% chance to expire worthless and a 0.57% yield (3.31% annualized). A $25.00 call can be sold for $0.50 as a covered-call from the current price (≈40% OTM), producing a 42.78% total return if called at March 20 expiration, or a 2.80% immediate yield boost (16.23% annualized) with a 56% chance to expire worthless. Implied volatilities are elevated (put IV 90%, call IV 168%) versus a trailing 12-month realized volatility of 72%; Stock Options Channel is tracking contract odds and histories for these trades.

Analysis

Market structure: The asymmetric IV skew (calls IV 168% vs puts IV 90%; trailing vol 72%) signals concentrated demand for upside exposure in ADPT and rich call premium that benefits option sellers and market-makers while penalizing buyers. Short-dated sellers of premium (cash-secured puts, covered calls, call-credit spreads) are the direct winners if no binary catalyst arrives before March 20; retail/volatile long holders are the likely losers on time decay. Cross-asset impact is limited but a volatility-driven move in ADPT could ripple into small-cap biotech ETFs (IBB) and raise sector hedging flows, slightly steepening risk premia and pressuring short-term high-yield credit if broader risk-off emerges.

Risk assessment: Tail risks are dominated by biotech-specific binaries — negative trial/FDA news or an emergency secondary offering could drop shares >40% (low-probability, high-impact). Immediate (days) risk: gamma pinch into March 20 expiry; short-term (weeks) risk: data/financing headlines; long-term (quarters) risk: revenue monetization/dilution. Hidden dependency: high call IV suggests concentrated directional retail buying or hedged institutional block trades — a gamma squeeze could produce rapid upside that penalizes naked sellers. Key catalysts to watch 30–60 days: any ADPT clinical readouts, analyst notes, or S-3 filings.

Trade implications: Primary tactical play is selling premium, not buying it. Execute cash-secured 17.50 puts (Mar 20) at $0.10 to collect ~0.57% yield (annualized ~3.3%), position-size 1–2% portfolio, accept 42% assignment probability and set buy-stop to close at IV compression to <60%. Alternatively, buy shares up to $17.86 and sell the Mar20 $25 covered call for $0.50 (target capped return 42.8%) only if comfortable capping upside; keep position <2% portfolio.

Contrarian angles: The market is likely overpricing short-dated call upside — selling call spreads captures rich premium with bounded risk; consider a 25/30 Mar20 call credit spread (size 0.5–1% portfolio) instead of naked short calls. Conversely, if you are long-term bullish on ADPT fundamentals, avoid near-term call purchases because front-month IV is inflated ~>90pts vs realized; buy deep-dated LEAPs beyond 9–12 months post any binary events to avoid near-term gamma risk.

Key Decisions for Investors

• Sell cash-secured ADPT Mar 20 $17.50 puts at $0.10 (collect $10) size 1–2% portfolio; target cost basis $17.40 if assigned, max downside stop-loss/close if ADPT < $15 (≈-16%) or if IV compresses below 60%.
• Buy ADPT shares up to $17.86 and sell Mar 20 $25 covered calls for $0.50 as a capped-yield trade (expected 42.8% if called); keep position ≤2% portfolio and close/roll if price > $22 to avoid large assignment risk.
• Sell a Mar 20 call-credit spread (ADPT 25/30) to harvest call-rich IV; size 0.5–1% portfolio, max loss defined (5.00 width minus credit), close if underlying moves >10% intraday or IV spikes >+30 pts.
• Avoid buying short-dated calls or adding >3% long-equity exposure until 30–60 days after any ADPT clinical/financing headlines; if bullish long-term, instead buy LEAPs (9–12+ months) after IV normalizes below 100%.